Long-term serum platinum changes and their association with cisplatin-related late effects in testicular cancer survivors. (3rd October 2018)

• Record Type: Journal Article
• Authors: Hjelle, Line V.; Gundersen, Per O. M.; Hellesnes, Ragnhild; Sprauten, Mette; Brydøy, Marianne; Tandstad, Torgrim; Wilsgaard, Tom; Fosså, Sophie D.; Oldenburg, Jan; Bremnes, Roy M.; Haugnes, Hege S.
• Is Part Of: Acta oncologica. Volume 57:Number 10(2018)
• Page Start: 1392
• Page End: 1400
• Publication Date: 2018-10-03
• Subjects: Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• DOI: 10.1080/0284186X.2018.1473641
• Languages: English
• ISSNs: 0284-186X

Abstract

Abstract: Background: The long-term toxicities after cisplatin-based chemotherapy (CBCT) reveal a remarkable inter-individual variation among testicular cancer survivors (TCSs). Therefore, we assessed long-term platinum (Pt) changes and their associations with CBCT-related late effects in TCSs. Material and methods: In 77 TCSs treated with CBCT from 1984 to 1990, blood samples for analyses of Pt and a questionnaire including self-reported neuro- and ototoxicity (NTX) symptoms were collected during two follow-up surveys at median 12 (Survey I; SI) and 20 (Survey II; SII) years after treatment. Information about second cancers after SII was retrieved from the Norwegian Cancer Registry. Results: A larger Pt decline from SI to SII was associated with a decreased risk of a second cancer diagnosis (HR 0.78, 95% CI 0.62–0.99 per 10 ng/L/year), and worsening of paresthesias in hands (OR 1.98, 95% CI 1.09–3.59 per 10 ng/L/year) and tinnitus (OR 1.51, 95% CI 1.01–2.27 per 10 ng/L/year). Conclusion: In summary, we found a significant association between a larger Pt decline and a reduced risk of second cancers and deterioration of paresthesias in hands and tinnitus.